BTOG 2023 | Surgical experience after neoadjuvant chemo-immunotherapy

Jonathan Spicer, BSc (Hon), MD, PhD, FRCS, McGill University, Montreal, Canada, describes his experience of operating patients who have received neoadjuvant chemo-immunotherapy. He chooses to operate in this way as it frequently provides an opportunity for less invasive, less extensive surgery and overall, improved survival outcomes. Despite common reservations towards this method, data suggests that generally, chemo-immunotherapy doesn’t significantly change the complication profile when compared with first-line surgery or neoadjuvant chemotherapy. This interview took place at the British Thoracic Oncology Group (BTOG) Annual Conference 2023 in Belfast, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.